论文部分内容阅读
目的试论氨溴索、复方异丙托溴胺、布地奈德、联合雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法 100例慢性阻塞性肺疾病急性加重期患者,按照不同的治疗手段将其随机分为观察组和对照组,每组50例。对照组患者进行常规治疗的基础上加用15 mg氨溴索采用氧气驱动雾化吸入,观察组患者进行常规治疗的基础上加用2 ml布地奈德、2.5 ml复方异丙托溴胺,采用氧气雾化吸入,对比分析两组患者的临床疗效。结果观察组患者的总有效率为92.0%,高于对照组的82.0%,差异有统计学意义(P<0.05)。观察组患者的咳嗽消失时间、哮鸣音消失时间、喘息缓解时间、肺部啰音消失时间显著优于对照组患者,差异有统计学意义(P<0.05)。结论对慢性阻塞性肺疾病急性加重期患者常规治疗的基础上加用布地奈德、复方异丙托溴胺,采用氧气雾化吸入,疗效显著,不良反应发生率低,大大的缩短了住院时间,具有临床价值意义,可以大力推广。
Objective To evaluate the clinical efficacy of ambroxol, ipratropium bromide, budesonide combined with inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods 100 cases of patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into observation group and control group according to different treatment methods, 50 cases in each group. The patients in the control group were treated with inhalation of 15 mg ambroxol by aerosol inhalation. The patients in the observation group were treated with 2 ml budesonide and 2.5 ml compound ipratropium bromide. Oxygen inhalation, comparative analysis of two groups of patients with clinical efficacy. Results The total effective rate of observation group was 92.0%, which was higher than that of control group (82.0%), the difference was statistically significant (P <0.05). Patients in the observation group had significantly shorter cough disappearance time, wheeze disappearance time, wheezing relief time, and pulmonary rales disappearance time than those in the control group (P <0.05). Conclusion Budesonide and Ipratropium bromide combined with inhalation of oxygen inhalation based on the routine treatment of patients with acute exacerbation of chronic obstructive pulmonary disease have significant curative effect and low incidence of adverse reactions, greatly shortening the length of hospital stay , With clinical significance, can be vigorously promoted.